Schittecatte M, Garcia-Valentin J, Charles G, Machowski R, Pena-Othaitz M J, Mendlewicz J, Wilmotte J
Département de Psychiatrie, Hôpital Vincent Van Gogh, Marchienne-au-Pont, Belgium.
J Affect Disord. 1995 Mar 14;33(3):151-7. doi: 10.1016/0165-0327(94)00059-i.
We have shown that clonidine, infused i.v. during the second non-REM period, was significantly less REM sleep suppressant in depressed patients than in control subjects. We have named this procedure the 'clonidine REM suppression test (CREST)'. In this report, we compare in the same sample (15 patients with primary major affective illness, 10 normal controls, 15 patients with minor depression and 15 patients with generalized anxiety) the efficacy of the CREST to separate the major depressed patients from the control subjects with the efficacy of three currently proposed biological markers of depression, i.e., the latency of REM sleep, the dexamethasone suppression test and the clonidine growth hormone stimulation test. We found that the CREST had the highest efficacy and suggest that further studies with independent and larger samples of patients and controls are needed to confirm those preliminary results and establish if the CREST could provide a new biological marker of major affective disorders.
我们已经表明,在第二个非快速眼动睡眠期静脉注射可乐定,抑郁症患者的快速眼动睡眠抑制作用明显低于对照组。我们将此程序命名为“可乐定快速眼动睡眠抑制试验(CREST)”。在本报告中,我们在同一组样本(15例原发性重度情感性疾病患者、10例正常对照、15例轻度抑郁症患者和15例广泛性焦虑症患者)中,比较了CREST将重度抑郁症患者与对照对象区分开来的功效,以及目前提出的三种抑郁症生物学标志物的功效,即快速眼动睡眠潜伏期、地塞米松抑制试验和可乐定生长激素刺激试验。我们发现CREST具有最高的功效,并建议需要用独立且更大样本的患者和对照进行进一步研究,以证实这些初步结果,并确定CREST是否能提供一种新的重度情感障碍生物学标志物。